1-(氯氨基)金刚烷 | 24375-06-2

• 分子结构分类: 有机化合物 - 有机氮化合物
• 中文名称: 1-(氯氨基)金刚烷
• 英文名称: 1-(Chloroamino)adamantane
• 英文别名: 1-N-Chloraminoadamantan；N-chloroadamantan-1-amine
• CAS: 24375-06-2
• 化学式: C₁₀H₁₆ClN
• 分子量: 185.697
• InChiKey: NWKBFPZBSLWSIQ-UHFFFAOYSA-N

物化性质

• 熔点：
  133-134 °C
• 沸点：
  249.6±23.0 °C(Predicted)
• 密度：
  1.16±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  4.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  12
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  1-(氯氨基)金刚烷 以52%的产率得到
  参考文献：
  名称：

  ROBERTS J. T.; RITTBERG B. R.; KOVACIC P.; SCALZI F. V.; SEELY M. J., J. ORG. CHEM., 1980, 45, NO 26, 5239-5243

  摘要：

  DOI：
• 作为产物：
  描述：

  金刚烷胺 、 Calciumhypochlorite 以93%的产率得到
  参考文献：
  名称：

  ROBERTS J. T.; RITTBERG B. R.; KOVACIC P.; SCALZI F. V.; SEELY M. J., J. ORG. CHEM., 1980, 45, NO 26, 5239-5243

  摘要：

  DOI：

文献信息

• [EN] SYNTHESIS AND USE OF VILDAGLIPTIN FOR THE PREPARATION OF PHARMACEUTICAL DOSAGE FORMS<br/>[FR] SYNTHÈSE ET UTILISATION DE VILDAGLIPTINE POUR PRÉPARER DES FORMES GALÉNIQUES PHARMACEUTIQUES
  申请人：KRKA D D NOVO MESTO

  公开号：WO2011012322A2

  公开（公告）日：2011-02-03

  The present invention relates the synthesis of vildagliptin in the presence of phase transfer catalysts; as well as the use of vildagliptin or its pharmaceutically acceptable salts for the preparation of solid oral dosage forms.

  本发明涉及在相转移催化剂的存在下合成维格列汀；以及利用维格列汀或其药学上可接受的盐制备固体口服剂量形式的用途。
• SOLUBLE EPOXIDE HYDROLASE INHIBITORS
  申请人：Patel Dinesh

  公开号：US20080200467A1

  公开（公告）日：2008-08-21

  Disclosed are alpha keto amide and alpha hydroxy amide compounds and compositions that inhibit soluble epoxide hydrolase (sEH), methods for preparing the compounds and compositions, and methods for treating patients with such compounds and compositions. The compounds, compositions, and methods are useful for treating a variety of sEH mediated diseases, including hypertensive, cardiovascular, inflammatory, pulmonary, and diabetic-related diseases.

  本发明涉及抑制可溶性环氧水解酶（sEH）的α酮酰胺和α羟基酰胺化合物和组合物，制备这些化合物和组合物的方法，以及使用这些化合物和组合物治疗患者的方法。这些化合物、组合物和方法可用于治疗各种sEH介导的疾病，包括高血压、心血管、炎症、肺部和糖尿病相关疾病。
• Thermolysis of N,N-dihalo derivatives of bridgehead and neopentylamines to the corresponding halides
  作者：John T. Roberts、Barry R. Rittberg、Peter Kovacic、Francis V. Scalzi、Michael J. Seely

  DOI：10.1021/jo01314a003

  日期：1980.12
• Heterobicyclic metalloprotease inhibitors
  申请人：Steeneck Christoph

  公开号：US20070155738A1

  公开（公告）日：2007-07-05

  The present invention relates generally to amide group containing pharmaceutical agents, and in particular, to amide containing heterobicyclic metalloprotease inhibitor compounds. More particularly, the present invention provides a new class of heterobicyclic MMP-13 inhibiting and MMP-3 inhibiting compounds, that exhibit an increased potency in relation to currently known MMP-13 and MMP-3 inhibitors.
• Oral Pharmaceutical Composition for Targeted Transport of a Platinum Complex Into the Colorectal Region, Method for Producing and Use as Medicament Thereof
  申请人：Franc Ales

  公开号：US20070232819A1

  公开（公告）日：2007-10-04

  An oral pharmaceutical composition for targeted transport of a platinum complex into the colorectal region, includes a mixture of platinum complex of general formula I wherein A each independently is an —NH 3 group or an amino group containing 1 to 18 carbon atoms, B each independently is a halogen atom, a hydroxy group or a —O—C(O)—R group wherein R each independently is hydrogen atom or an alkyl, alkenyl, aryl, aralkyl, alkylamino or alkoxy group containing 1 to 10 carbon atoms or functional derivatives of these groups, and X each independently is a halogen atom or a monocarboxylate group containing 1 to 20 carbon atoms, or X together form a dicarboxylate group containing 2 to 20 carbon atoms, and at least one excipient selected from the group including a saccharide, oligosaccharide, polysaccharide, modified polysaccharide mucopolysaccharide, protein, oligoprotein, polyprotein, mucoprotein, peptide, oligopeptide and polypeptide, and optionally a lubricant and/or disintegrant, which mixture is optionally compressed into a tablet or contained in a capsule, and this tablet or capsule is optionally coated with a biodegradable layer and/or an outer pH-sensitive colonic layer, and a method of manufacturing and using the composition for treatment of colorectal carcinoma.